Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
MAGMA (MAGMA) fluctuates 53.4% in 24 hours: Driven by Magma2.0 launch and abnormal trading volume

MAGMA (MAGMA) fluctuates 53.4% in 24 hours: Driven by Magma2.0 launch and abnormal trading volume

Bitget PulseBitget Pulse2026/04/25 22:03
Show original
By:Bitget Pulse

Volatility Brief

In the past 24 hours, MAGMA's price rebounded from a low of $0.18701 to a high of $0.28687, currently at $0.19706, with a fluctuation range reaching 53.4%. The 24-hour spot trading volume is approximately $1.82 million, while futures trading volume soared to $49.8 million, a significant increase compared to the previous day.

Analysis of Abnormal Movements

- Official launch of Magma 2.0: Sui chain’s first AI-driven Prop AMM supporting millisecond-level volatility prediction, RFQ dark pool, and zero slippage, directly pushing the price from a low of $0.19078 to $0.26763.

- Abnormal trading volume and surge in purchases: 24-hour trading volume expanded to $3.9 million - $12.7 million, with monitoring data showing abnormal buying activities up to 9.3 times, accompanied by active futures markets.

Market Opinions and Outlook

Community sentiment leans optimistic, with discussions on X platform highlighting gains of 40%-61.9%. Traders focus on liquidity capture opportunities; analysts warn that the low-liquidity microcap characteristic can easily trigger speculative pumps. It is advised to be cautious of short-term pullback risks and pay attention to on-chain capital flows and Sui ecosystem trends.

Note: This analysis is automatically generated by AI based on public data and on-chain monitoring and is for informational purposes only.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million

RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.

智通财经2026/09/21 16:16